Pharma

Your Article Summary

See Latest Articles

Avigen Granted AV411 Patent for Neuropathic Pain
Avigen, 05/21/09

Avigen, Inc. a biopharmaceutical company, announced that it has been granted United States Patent No. 7,534,806, entitled "Method for Treating Neuropathic Pain and Associated Syndromes." The patent covers the treatment of neuropathic pain with therapeutic doses of AV411, including syndromes like diabetic neuropathy, post-herpetic neuralgia, and fibromyalgia, and neuropathic pain associated with stroke or accompanying cancer chemotherapy. Avigen anticipates additional patents will be issued covering indications that include addiction, delirium, and psychotic disorders, as well as composition of matter claims on AV411 analogs. AV411 is marketed in Japan but not approved for any indication in the United States.

Today in Drug/Product Approvals...keeping you current

Receive free subspecialty "5-minute updates" via email

Human genome sciences announces submission of marketing authorization application to emea for joulferon
Human Genome Sciences, 12/15/09

Mylan Receives Approval for Generic Version of Antiepileptic Keppra 1000 mg
Mylan, 12/15/09

FDA Advisory Committee Supports Use of Aztreonam for Inhalation Solution for Patients with Cystic Fibrosis
Gilead, 12/14/09

 See all of Drug/Product Approvals